Please help us spread the word. We are hiring postdoctoral fellows in Clinical Epidemiology and Pharmacoepidemiology. Details and application via Indeed.

Honored to speak at Harvard’s Radcliffe Institute workshop on #LongCOVID. I am energized by our 2 days of brainstorming about the road ahead. The challenges are real, but I’m leaving hopeful. Millions living with Long Covid are counting on our progress—we must keep keep pushing forward!!!

For decades, the junk food industry has deliberately engineered foods to be addictive. GLP-1 drugs have helped people break free from this cycle. The industry is now searching for ways to undo the effects of these meds, aiming to design foods that remain addictive for those on GLP1. buff.ly/40QHDnk

GLP-1 drugs are revolutionizing the way we think about obesity. It is a chronic disease (like high blood pressure), and might actually be a form of food addiction. One reason these drugs are so effective in treating obesity could be that they address the underlying addiction.

New Long Covid policy paper from Norway outlines knowledge gaps and lessons learnt for developing preparedness for future pandemics. Section 5 (pictured below) outlines their recommendations. Led by Sara Illman, PhD and colleagues. www.nordforsk.org/2025/knowled...

Alzheimer, addictions, dépression… les effets bénéfiques de l’Ozempic et des médicaments apparentés My Ozempic piece has been translated into French; thanks the amazing team at Conversation in Paris. @theconversation.com @france.theconversation.com theconversation.com/alzheimer-ad...

I talked to Dani Blum from @nytimes.com about the potential role of GLP-1 drugs (Ozepmic and similar drugs) on Alzheimer’s disease. They seem promising, but more data is needed. www.nytimes.com/2025/01/31/w...

🚨 ICYMI: Our latest study shows that the popular GLP-1 weight loss drugs (e.g. Ozempic) have broad health benefits — reducing risks of 42 health conditions. They are not without risks — increasing risks of of 19 health conditions. www.nature.com/articles/s41...

📄 Free access to the full study: rdcu.be/d6VYU New from my team: In a study of over 2 million people, we comprehensively mapped the benefits and risks of GLP-1 (e.g. Ozempic and similar weight loss drugs) across 175 health conditions. Please share and download before it goes back behind paywall.

The latest from my team in Nature Medicine. We comprehensively mapped the benefits and risks of GLP-1 receptor agonists (GLP-1) (Ozempic, Wegovy, Mounjaro, Zepbound). By @Biostayan, Taeyoung Choi and me A 🧵 www.nature.com/articles/s41...

My first post has to be about #LongCOVID 🔹 400 million individuals affected worldwide 🔹 $1 trillion in annual economic costs 🔹 Countless lives & communities shattered The time for a comprehensive policy and research response is now! Details in our review here www.nature.com/articles/s41...